Development

An expert from Aptamer Group reveals the potential of Optimers (a type of aptamer) in the realm of drug delivery, including its targeting capabilities, scalability, and key differences between Optimers and antibody-drug conjugates.

External expertise is beneficial in helping companies select the right tools at the right stages of development to ensure success.

There are many benefits of employing a reformulation strategy, but companies must also overcome a variety of challenges too.

Numerous benefits will eventually lead to large-scale applications in pharmaceutical manufacturing.

Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.

Some of the greatest advancements in drug delivery are related to disposable delivery devices, vaccine adjuvants, and wearable pumps, according to Nicholas W. Warne of Pfizer.

FDA is highlighting how the Patient-Focused Drug Development program has encouraged active involvement of many patient groups in bringing their perspectives into the process of developing, testing, and approving new medicines.

A combination of eye imaging techniques and adaptive optics has revealed key details of choroideremia.

The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.

Roquette’s acquisition of Crest Cellulose is designed to reinforce its presence in India and other countries in Asia.

CytoReason has announced an expanded collaboration deal with Pfizer to deliver AI for drug discovery and development.

Experts from Umoja Biopharma dive into cell therapy development in this episode of the Drug Solutions Podcast, including the greatest advancements in cell therapy to date, areas for improvement, the biggest trends in cell therapy development, and retention as a pain point.

Novo Nordisk and Microsoft are collaborating to accelerate drug discovery and development using big data and artificial intelligence.

Ensysce Biosciences and Quotient Sciences are partnering to develop and test Ensysce’s novel opioid designed to prevent abuse and overdose.

Automation enables intensification of downstream processes.

How Pfizer’s external-facing research and development scientists uncover the most promising emerging therapy concepts and ideas in the pharmaceutical landscape.

The flow of capital and scientific acuity irrigates this pharm system.

Biopharmaceutical manufacturers must consider a surprisingly wide range of factors when deciding where to turn for assistance with cell line development.

It is argued that orthogonal quantitative methods can be used to establish primary working standards. An example details how to calculate the expanded measurement uncertainty (U) for the certified assay value by considering two orthogonal assay methods.

API permeation into the skin modulates the efficacy of topical treatments.

It is possible to overcome some of the limitations of traditional dosage forms by employing alternative drug delivery formulation strategies.

Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.

Pharmaceutical Technology spoke with Andrew Anderson, Global Head Strategic Account Management and Mary Todas, Director Technical Development and Regulatory Affairs, both with Pfizer CentreOne, about best practices for API quality.

Scientists have developed a mouse model that could be a promising model system for research into factors affecting mammalian embryonic development and disease.

ProBioGen will collobarate with NextPoint Therapeutics to develop and manufacture its lead antibody candidate.

In this episode of the Drug Solutions Podcast, John Koleng, VP of product development and manufacturing for TFF Pharmaceuticals shares outsourcing strategies in biopharma.

Merck, known as MSD outside of the United States and Canada, will collaborate with Cerevance to identify novel targets for Alzheimer’s disease.

Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).

Synthego has launched new engineered cell libraries to validate targets for quicker drug discovery timelines.

This article reviews sources of excipient variability, including raw materials and processing, both of which may vary from supplier to supplier and from plant to plant for a single manufacturer.